Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome

Inclusion Criteria: * Patients with recent or current ischemic symptoms at the time of randomization will be eligible if 2 of the following criteria are met: ST-T change indicating ischemia; a positive test of biomarker indication myocardial necrosis; or one of several risk factors(age ≥60 years * Previous myocardial infarction or coronary artery bypass grafting \[CABG\] * Coronary artery disease with stenosis of ≥50% in at least two vessels * Previous ischemic stroke, transient ischemic attack, carotid stenosis of at least 50%, or cerebral revascularization * Diabetes mellitus * Peripheral arterial disease; or chronic renal dysfunction, defined as a creatinine clearance of \<60 ml per minute per 1.73 m2 of body surface area) Exclusion Criteria: 1. Administration of fibrinolytic or any GP IIb/IIIa inhibitors for the treatment of current AMI 2. Major surgery or trauma within 30 days 3. Active bleeding 4. Previous stroke in the last six months 5. Oral anticoagulant therapy 6. Pre-existing thrombocytopenia 7. Vasculitis 8. Hypertensive retinopathy 9. Severe hepatic failure 10. Severe renal failure requiring hemodialysis 11. Documented allergy/intolerance or contraindication to tirofiban or P2Y12 inhibitor 12. Uncontrolled hypertension (systolic or diastolic arterial pressure \>180 mmHg or 120, respectively, despite medical therapy) 13. Limited life expectancy, e.g. neoplasms, others 14. Inability to obtain informed consent